TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
TEL AVIV, Israel, Sept. 28, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview via a Fireside Chat format at the Chardan Gene Therapy Conference, being held October 10th at the Westin New York Grand Central hotel in New York City.
Presentation Details:
Date: Tuesday, October 10
Time: 1:45pm Eastern Time.
Webcast: http://wsw.com/webcast/chard/vblt/
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
[email protected]
(646) 597-6979
MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
(646) 627-8384
